Safety and Clinical Outcomes when Utilizing High-Dose (≥8 mg/kg) Daptomycin Therapy

Vancomycin: Understanding Its Past and Preserving Its Future

(2011) Donald P. Levine   SOUTHERN MEDICAL JOURNAL

Relationship between Susceptibility to Daptomycin In Vitro and Activity In Vivo in a Rabbit Model of Aortic Valve Endocarditis

(2009) H. F. Chambers et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety of High‐Dose Intravenous Daptomycin Treatment: Three‐Year Cumulative Experience in a Clinical Program

(2009) D. A. Figueroa et al.   CLINICAL INFECTIOUS DISEASES

Evaluation of Daptomycin Pharmacodynamics and Resistance at Various Dosage Regimens against Staphylococcus aureus Isolates with Reduced Susceptibilities to Daptomycin in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations

(2008) W. E. Rose et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin

(2008) T. P. Lodise et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial-Resistant Pathogens in Intensive Care Units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) Study, 2005-2006

(2008) G. G. Zhanel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Increasing Antibiotic Resistance among Methicillin‐ResistantStaphylococcus aureusStrains

(2008) George Sakoulas et al.   CLINICAL INFECTIOUS DISEASES

Epidemiology of Methicillin‐ResistantStaphylococcus aureus

(2008) Helen W. Boucher et al.   CLINICAL INFECTIOUS DISEASES

Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006)

(2008) Mariana Castanheira et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections

(2008) Donald I. Hsu et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria

(2008) D. E. Katz et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Influence of Vancomycin Minimum Inhibitory Concentration on the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia

(2007) A. Soriano et al.   CLINICAL INFECTIOUS DISEASES